{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T06:04:59Z","timestamp":1782453899353,"version":"3.54.5"},"reference-count":46,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Antimicrobial drugs to treat male urinary tract infection (UTI) with multidrug-resistant Enterobacterales are limited. We studied oral fosfomycin-trometamol (FT) in this situation. The objective was to assess the clinical cure rate in patients presenting UTIs treated with oral FT. Methods: We conducted a single-center observational retrospective study from January 2017 to August 2018. The primary endpoint was clinical cure; and the secondary endpoints were incidence of recurrences, oral FT safety, and microbiological cure. Results: Sixteen male patients were included, presenting 21 UTI episodes. Fourteen patients (88%) have at least one underlying urologic disorder. We described 4 episodes of acute UTI and 17 episodes of chronic bacterial prostatitis (CBP). Sixteen out of twenty-one Enterobacterales were extended spectrum beta-lactamase (ESBL)-producers and all the patients presented a resistance to fluoroquinolones and trimethoprim\/sulfamethoxazole. In acute UTI, the regimen was a daily dose of oral FT for a mean duration of 2.5 weeks (+\/\u22127.0 days). Clinical and microbiological recovery was achieved in all patients, with no recurrence after 5.3 months follow-up on average (+\/\u221210.4 days). In CBP, the regimen was one oral dose of fosfomycin every 24\u201348 h, for a mean duration of 5.5 weeks\/UTI episodes (+\/\u221215.3 days). Clinical and microbiological recovery was found in 16\/17 cases. Seven of the twelve patients with CBP had relapsed and 3\/12 had had a new episode of infection after an average follow-up of 5.8 months. Only 6\/21 of patients presented minor or moderate adverse effects, such as digestive disorders. Conclusions: FT could be an alternative option to carbapenems in the treatment of multidrug-resistant Enterobacterales infections for male UTIs.<\/jats:p>","DOI":"10.3390\/antibiotics11020198","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T11:35:17Z","timestamp":1643974517000},"page":"198","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and Safety of Oral Fosfomycin-Trometamol in Male Urinary Tract Infections with Multidrug-Resistant Enterobacterales"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2177-4318","authenticated-orcid":false,"given":"K\u00e9vin","family":"Bouiller","sequence":"first","affiliation":[{"name":"Department of Infectious and Tropical Diseases, CHRU, 25000 Besan\u00e7on, France"},{"name":"Unit\u00e9 Mixte de Recherche Centre National de la Recherche Scientifique (UMR CNRS) 6249 Chrono-Environnement, University of Bourgogne Franche-Comt\u00e9, 25000 Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3177-9806","authenticated-orcid":false,"given":"Souheil","family":"Zayet","sequence":"additional","affiliation":[{"name":"Tropical and Infectious Diseases Department, Hospital Nord Franche-Comt\u00e9, 90400 Tr\u00e9venans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul-Emile","family":"Lalloz","sequence":"additional","affiliation":[{"name":"Department of Infectious and Tropical Diseases, CHRU, 25000 Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Potron","sequence":"additional","affiliation":[{"name":"Bacteriology Laboratory, CHRU, 25000 Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9220-9359","authenticated-orcid":false,"given":"Vincent","family":"Gendrin","sequence":"additional","affiliation":[{"name":"Tropical and Infectious Diseases Department, Hospital Nord Franche-Comt\u00e9, 90400 Tr\u00e9venans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chirouze","sequence":"additional","affiliation":[{"name":"Department of Infectious and Tropical Diseases, CHRU, 25000 Besan\u00e7on, France"},{"name":"Unit\u00e9 Mixte de Recherche Centre National de la Recherche Scientifique (UMR CNRS) 6249 Chrono-Environnement, University of Bourgogne Franche-Comt\u00e9, 25000 Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4334-9889","authenticated-orcid":false,"given":"Timoth\u00e9e","family":"Klopfenstein","sequence":"additional","affiliation":[{"name":"Tropical and Infectious Diseases Department, Hospital Nord Franche-Comt\u00e9, 90400 Tr\u00e9venans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.medmal.2018.03.005","article-title":"Practice guidelines for the management of adult community-acquired urinary tract infections","volume":"48","author":"Caron","year":"2018","journal-title":"M\u00e9d. Mal. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1404813","DOI":"10.1155\/2018\/1404813","article-title":"Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli","volume":"2018","author":"Zhanel","year":"2018","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"ref_3","unstructured":"Talon, D., Hocquet, D., and Bertrand, X. (2022, January 11). Infections Nosocomiales. Available online: http:\/\/www.em-consulte.com\/en\/article\/962550."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.mib.2006.08.011","article-title":"The CTX-M beta-lactamase pandemic","volume":"9","author":"Coque","year":"2006","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e966","DOI":"10.1016\/j.ijid.2013.04.005","article-title":"Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey","volume":"17","author":"Demir","year":"2013","journal-title":"Int. J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","article-title":"Extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: An emerging public-health concern","volume":"8","author":"Pitout","year":"2008","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S1473-3099(14)70780-7","article-title":"Global antibiotic consumption 2000 to 2010: An analysis of national pharmaceutical sales data","volume":"14","author":"Gandra","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"48.e9","DOI":"10.1016\/j.cmi.2016.09.003","article-title":"Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States","volume":"23","author":"Bartsch","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s15010-016-0910-2","article-title":"Incidence of urinary tract infections and antibiotic resistance in the outpatient setting: A cross-sectional study","volume":"45","author":"Rossignol","year":"2017","journal-title":"Infection"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jinf.2015.11.009","article-title":"Prevalence of extended-spectrum beta-lactamase producing Escherichia coli in community-onset urinary tract infections in France in 2013","volume":"72","author":"Martin","year":"2016","journal-title":"J. Infect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"106489","DOI":"10.1016\/j.ijantimicag.2021.106489","article-title":"Investigation of In-vitro Efficacy of Intravenous Fosfomycin in Extensively Drug-Resistant Klebsiella pneumoniae Isolates and Effect of Glucose 6-Phosphate on Sensitivity Results","volume":"59","author":"Aydemir","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lee, Y.-L., Chen, H.-M., Hii, I.-M., and Hsueh, P.-R. (2022). Carbapenemase-producing Enterobacterales infections: Recent advances in diagnosis and treatment. Int. J. Antimicrob. Agents, 106528.","DOI":"10.1016\/j.ijantimicag.2022.106528"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Bjerklund Johansen, T.E., Kulchavenya, E., Lentz, G.M., Livermore, D.M., Nickel, J.C., Zhanel, G., and Bonkat, G. (2021). Fosfomycin Trometamol for the Prevention of Infectious Complications After Prostate Biopsy: A Consensus Statement by an International Multidisciplinary Group. Eur. Urol. Focus, in press.","DOI":"10.1016\/j.euf.2021.11.007"},{"key":"ref_14","unstructured":"(2022, January 11). Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Available online: https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciab934\/6429720."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijantimicag.2018.03.014","article-title":"What non-carbapenem antibiotics are active against ESBL-producing enterobacteriaceae ?","volume":"52","author":"Bouxom","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1128\/AAC.02611-15","article-title":"Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis","volume":"60","author":"Pigrau","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/jac\/dkz015","article-title":"Oral fosfomycin for the treatment of chronic bacterial prostatitis","volume":"74","author":"Karaiskos","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/cid\/civ436","article-title":"Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs","volume":"61","author":"Grayson","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1590\/0037-8682-0289-2014","article-title":"Successful treatment of lower urinary tract infections with oral fosfomycin: A report of three cases","volume":"48","author":"Silva","year":"2015","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1093\/cid\/cit704","article-title":"Is Fosfomycin a Potential Treatment Alternative for Multidrug-Resistant Gram-Negative Prostatitis?","volume":"58","author":"Gardiner","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000222037","article-title":"Effect of Fosfomycin on the Fecal Microflora of Man","volume":"23","author":"Hendlin","year":"1977","journal-title":"Chemotherapy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/jac\/dki169","article-title":"Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis","volume":"56","author":"Gupta","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000074526","article-title":"Penetration of Antimicrobial Agents into the Prostate","volume":"49","author":"Charalabopoulos","year":"2003","journal-title":"Chemotherapy"},{"key":"ref_25","unstructured":"Colombier, M.-A., and Lafaurie, M. (2022, January 11). Infections Urinaires Masculines. Available online: http:\/\/www.edimark.fr\/infection-urinaire-masculine."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1128\/AAC.00402-12","article-title":"Experience with Fosfomycin for Treatment of Urinary Tract Infections Due to Multidrug-Resistant Organisms","volume":"56","author":"Neuner","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e004157","DOI":"10.1136\/bmjopen-2013-004157","article-title":"Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: An uncontrolled, open-label, multicentre study","volume":"3","author":"Qiao","year":"2013","journal-title":"BMJ Open"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2006.08.039","article-title":"Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections","volume":"29","author":"Pullukcu","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1179\/joc.2010.22.5.355","article-title":"Carbapenem Versus Fosfomycin Tromethanol in the Treatment of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli-Related Complicated Lower Urinary Tract Infection","volume":"22","author":"Senol","year":"2010","journal-title":"J. Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijantimicag.2016.04.014","article-title":"Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum \u03b2-lactamase urinary tract infections","volume":"48","author":"Veve","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_31","unstructured":"Nagel, J.L., Washer, L., Kunapuli, A., Heidmann, J., Pisani, J., and Gandhi, T. (2022, January 11). Clinical Efficacy of Fosfomycin for the Treatment of Complicated Lower Tract and Uncomplicated Urinary Tract Infections. International Archives of Medicine. Available online: http:\/\/imed.pub\/ojs\/index.php\/iam\/article\/view\/1242."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0924-8579(03)00230-9","article-title":"In vitro activity of fosfomycin against Gram-negative urinary pathogens and the biological cost of fosfomycin resistance","volume":"22","author":"Marchese","year":"2003","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jama.2021.9899","article-title":"Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract Infection: A Randomized Clinical Trial","volume":"326","author":"Drekonja","year":"2021","journal-title":"JAMA"},{"key":"ref_34","unstructured":"(2022, January 11). Oral Fosfomycin for the Treatment of Chronic Prostatitis. Available online: https:\/\/www.researchgate.net\/profile\/Ilias_Karaiskos\/publication\/282135353_Oral_Fosfomycin_for_the_Treatment_of_Chronic_Prostatitis\/links\/56047c4b08ae5e8e3f30ec2e\/Oral-Fosfomycin-for-the-Treatment-of-Chronic-Prostatitis.pdf."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ijantimicag.2016.02.009","article-title":"Raoultella planticola chronic bacterial prostatitis with prostatic calcifications: Successful treatment with prolonged fosfomycin therapy","volume":"47","author":"Gian","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/jac\/dkv067","article-title":"Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis","volume":"70","author":"Rhodes","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Matthews, P.C., Barrett, L.K., Warren, S., Stoesser, N., Snelling, M., Scarborough, M., and Jones, S. (2016). Oral fosfomycin for treatment of urinary tract infection: A retrospective cohort study. BMC Infect. Dis., 16.","DOI":"10.1186\/s12879-016-1888-1"},{"key":"ref_38","unstructured":"(2022, January 11). KoreaMed Synapse. Available online: https:\/\/synapse.koreamed.org\/search.php?where=aview&id=10.4111\/icu.2018.59.3.187&code=2020ICU&vmode=FULL."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00345-013-1145-9","article-title":"The impact of biofilm-producing bacteria on chronic bacterial prostatitis treatment: Results from a longitudinal cohort study","volume":"32","author":"Bartoletti","year":"2014","journal-title":"World J. Urol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/QCO.0000000000000222","article-title":"Bacterial prostatitis","volume":"29","author":"Gill","year":"2016","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.biopha.2017.08.016","article-title":"Comprehensive overview of prostatitis","volume":"94","author":"Khan","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antinf.2016.07.004","article-title":"Fosfomycine, place et int\u00e9r\u00eat dans un contexte de multir\u00e9sistance","volume":"18","author":"Pourbaix","year":"2016","journal-title":"J. Anti-infectieux"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1128\/AAC.50.1.368-370.2006","article-title":"In Vitro Activity of Fosfomycin against Extended-Spectrum-\u03b2-Lactamase- Producing Escherichia coli and Klebsiella pneumoniae: Comparison of Susceptibility Testing Procedures","volume":"50","author":"Morillo","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ijantimicag.2014.12.019","article-title":"Persistent extended-spectrum \u03b2-lactamase-positive Escherichia coli chronic prostatitis successfully treated with a combination of fosfomycin and doxycycline","volume":"45","author":"Cunha","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/cid\/civ443","article-title":"Editorial Commentary: Fosfomycin: The Current Status of the Drug","volume":"61","author":"Falagas","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Antonello, R.M., Principe, L., Maraolo, A.E., Viaggi, V., Pol, R., Fabbiani, M., Montagnani, F., Lovecchio, A., Luzzati, R., and Di Bella, S. (2020). Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies. Antibiotics, 9.","DOI":"10.3390\/antibiotics9080500"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/2\/198\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:13:47Z","timestamp":1760134427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/2\/198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["antibiotics11020198"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11020198","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]}}}